MindMed Announces New Employee Inducement Grants
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for four new non-executive employees. The grants consist of options to purchase 88,950 common shares with an effective date of March 24, 2025.
The options' exercise price will match the closing price of MindMed's common shares on March 21, 2025. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the subsequent three years, contingent on continued employment. These grants, approved by MindMed's Compensation Committee on March 19, 2025, were issued outside the company's equity incentive plans as employment inducements under NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD), un'azienda biofarmaceutica clinica in fase avanzata focalizzata sui disturbi della salute mentale, ha annunciato concessioni di indennità per quattro nuovi dipendenti non esecutivi. Le concessioni consistono in opzioni per acquistare 88.950 azioni ordinarie con una data di efficacia del 24 marzo 2025.
Il prezzo di esercizio delle opzioni corrisponderà al prezzo di chiusura delle azioni ordinarie di MindMed del 21 marzo 2025. Il piano di maturazione si estende su quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni, a condizione di un'occupazione continuativa. Queste concessioni, approvate dal Comitato per la Compensazione di MindMed il 19 marzo 2025, sono state emesse al di fuori dei piani di incentivazione azionaria dell'azienda come indennità di assunzione ai sensi della Regola NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD), una empresa biofarmacéutica clínica en etapa avanzada centrada en trastornos de la salud mental, ha anunciado concesiones de incentivos para cuatro nuevos empleados no ejecutivos. Las concesiones consisten en opciones para comprar 88,950 acciones comunes con una fecha de efectividad del 24 de marzo de 2025.
El precio de ejercicio de las opciones coincidirá con el precio de cierre de las acciones comunes de MindMed del 21 de marzo de 2025. El calendario de adquisición se extiende por cuatro años, con el 25% adquiriendo derechos después del primer año y el restante 75% adquiriendo derechos mensualmente durante los tres años siguientes, condicionado a la continuidad del empleo. Estas concesiones, aprobadas por el Comité de Compensación de MindMed el 19 de marzo de 2025, se emitieron fuera de los planes de incentivos de capital de la empresa como incentivos laborales bajo la Regla NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD), 뇌 건강 장애에 중점을 둔 후기 단계 임상 생물 제약 회사가 네 명의 새로운 비임원 직원에게 유인 보상을 발표했습니다. 이 보상은 88,950주 보통주를 구매할 수 있는 옵션으로 구성되며, 유효 날짜는 2025년 3월 24일입니다.
옵션의 행사 가격은 2025년 3월 21일 MindMed의 보통주의 종가와 일치합니다. 취득 일정은 4년 동안 진행되며, 첫 해가 끝난 후 25%가 취득되고 나머지 75%는 이후 3년 동안 매월 취득됩니다. 이러한 보상은 2025년 3월 19일 MindMed의 보상 위원회에서 승인되었으며, NASDAQ 규칙 5635(c)(4)에 따른 고용 유인으로서 회사의 자본 인센티브 계획 외부에서 발행되었습니다.
MindMed (NASDAQ: MNMD), une entreprise biopharmaceutique en phase clinique avancée axée sur les troubles de la santé mentale, a annoncé des concessions d'incitation pour quatre nouveaux employés non exécutifs. Les concessions consistent en des options d'achat de 88 950 actions ordinaires avec une date d'effet du 24 mars 2025.
Le prix d'exercice des options sera égal au prix de clôture des actions ordinaires de MindMed du 21 mars 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25% acquis après la première année et les 75% restants acquis mensuellement au cours des trois années suivantes, sous réserve d'un emploi continu. Ces concessions, approuvées par le Comité de rémunération de MindMed le 19 mars 2025, ont été émises en dehors des plans d'incitation en actions de l'entreprise comme incitations à l'emploi conformément à la règle NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Störungen der Gehirngesundheit konzentriert, hat Anreizzahlungen für vier neue nicht-executive Mitarbeiter angekündigt. Die Zahlungen bestehen aus Optionen zum Kauf von 88.950 Stammaktien mit einem Wirksamkeitsdatum vom 24. März 2025.
Der Ausübungspreis der Optionen wird dem Schlusskurs der Stammaktien von MindMed am 21. März 2025 entsprechen. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig werden, abhängig von der fortgesetzten Beschäftigung. Diese Zahlungen, die am 19. März 2025 vom Vergütungsausschuss von MindMed genehmigt wurden, wurden außerhalb der Eigenkapitalanreizpläne des Unternehmens als Beschäftigungsanreize gemäß NASDAQ-Regel 5635(c)(4) ausgegeben.
- Successful attraction of new talent with equity-based compensation
- Long-term retention mechanism through 4-year vesting schedule
- Potential shareholder dilution from 88,950 new stock options
The Options were granted as a material inducement to each employee’s employment and were approved by MindMed's Compensation Committee on March 19, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324908287/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
How many shares are included in MindMed's (MNMD) March 2025 employee inducement grants?
What is the vesting schedule for MNMD's March 2025 employee stock options?
When will MindMed's (MNMD) March 2025 inducement grants become effective?
How many new employees received MNMD's March 2025 stock option grants?
